Theresa A. Guise, M.D., FASBMR
Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Professor, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1985 | University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, US, MD |
Postgraduate Training
| 1989-1992 | Clinical Fellowship, Endocrinology and Metabolism, University of Texas Health Science Center, San Antonio, Texas |
| 1986-1992 | Clinical Residency, Internal Medicine, University of Pittsburgh Health Center, Pittsburgh, Pennsylvania |
| 1985-1986 | Clinical Internship, Internal Medicine, University of Pittsburgh Health Center, Pittsburgh, Pennsylvania |
Licenses & Certifications
| 2023 | Drug Enforcement Agency |
| 1989 | Texas Medical Board License |
| 1988 | American Board of Internal Medicine |
| 1986 | National Board of Medical Examiners |
Experience & Service
Administrative Appointments/Responsibilities
Section Chief, Bone and Mineral Disorders, Department of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Other Professional Positions
Member, Molecular and Translational Biology and Therapeutics and Pharmacology, The University of Texas MD Anderson Cancer Center at Houston, Houston, Texas, 2024 - Present
Abell-Hanger Foundation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2022 - Present
Scholar, Cancer Prevention Research Institute of Texas, Houston, TX, 2021 - Present
Co-Director, Rolanette and Berdon Lawrence Bone Disease Program of Texas, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - Present
Jerry and Peg Throgmartin Professor of Oncology, Indiana University, Indianapolis, IN, 2009 - 2020
Gerald D. Aurbach Professor of Endocrinology, University of Virginia, Charlottesville, VA, 2002 - 2009
Extramural Institutional Committee Activities
Member, Endowed Positions and Awards Committee, The University of Texas MD Anderson Cancer Center, 2022 - Present
Member, Experimental Therapeutics/Systems Biology Joint Department Chair Search, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Multidisciplinary Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2021 - Present
Mentor, CPRIT TRIUMPH Postdoctoral Fellowship Training Grant, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Search Committee to select Cancer Center Director, Indiana University Simon Cancer Center, The University of Texas MD Anderson Cancer Center, 2019
Member, Indiana University, Review Panel Grand Challenges Grants, The University of Texas MD Anderson Cancer Center, 2015 - 2016
Member, Committee to select the Founding Dean, Richard M. Fairbanks School of Public Health, IUPUI, The University of Texas MD Anderson Cancer Center, 2012
Member, Physician Scientist Advisory Committee, Indiana University School of Medicine, The University of Texas MD Anderson Cancer Center, 2010 - 2013
Member, Strategic Planning Research Committee, Indiana University School of Medicine, The University of Texas MD Anderson Cancer Center, 2010 - 2012
Member, Research Advisory Committee, University of Virginia School of Medicine, The University of Texas MD Anderson Cancer Center, 2007 - 2009
Member, Committee to review reappointment of Dean, University of Virginia, The University of Texas MD Anderson Cancer Center, 2006
Member, Search Committee, Associate Dean for Clinical Research, University of Virginia, The University of Texas MD Anderson Cancer Center, 2004
Member, Howard Hughes Medical Institute Executive Committee, UTHSCSA, The University of Texas MD Anderson Cancer Center, 2002
Member, Internal Medicine Residency Selection Committee, UTHSCA, The University of Texas MD Anderson Cancer Center, 1998 - 2001
Member, Competitive Research Enhancement Fund Review Committee, UTHSCSA, The University of Texas MD Anderson Cancer Center, 1998 - 2002
Member, General Clinical Research Center Advisory Committee, UTHSCSA, The University of Texas MD Anderson Cancer Center, 1996 - 2001
Member, Institutional Animal Care and Use Committee, UTHSCSA, The University of Texas MD Anderson Cancer Center, 1996 - 2000
Member, Cancer Coordinating Committee, UTHSCSA, The University of Texas MD Anderson Cancer Center, 1995 - 1997
Member, Medical School Strategic Planning Committee, UTHSCSA, The University of Texas MD Anderson Cancer Center, 1995
Editorial Activities
Editor, Journal of Bone Oncology, 2015 - Present
Associate Editor, Primer on the Metabolic Bone Diseases and Disorders of Mineral, 7th Edition, 2009 - Present
Associate Editor, NCI Special Emphasis Panel for Breast Cancer Insight Awards, 2007 - 2012
Associate Editor, Journal of Bone and mineral Research, 2007 - 2012
Editor, Bone, 2006 - 2009
Editor/Service on Editorial Board(s), Bone, 2006 - 2009
Editor, Endocrinology, 2004
Editor/Service on Editorial Board(s), Endocrinology, 2004
Editor, Journal of Bone and Mineral Research, 2003 - 2008
Editor/Service on Editorial Board(s), Journal of Bone and Mineral Research, 2003 - 2008
Editor, Journal of Clinical Endocrinology and Metabolism, 2001 - 2004
Editor, Clinical and Translational Science, 2001
Editor/Service on Editorial Board(s), Journal of Clinical Endocrinology and Metabolism, 2001 - 2004
Honors & Awards
| 2021 - 2024 | Fellow, American Society for Bone and Mineral Research |
| 2021 - 2024 | Haddad Memorial Lecture, University of Pennsylvania |
| 2020 - 2024 | Cancer Prevention Research Institute of Texas (CPRIT) Scholar, Cancer Prevention Research Institute of Texas (CPRIT) |
| 2020 | Fellow of the American Society for Bone and Mineral Research |
| 2020 | Louis V. Avioli Memorial Lecture, American Society for Bone and Mineral Research |
| 2020 | Stephen M. Krane Award, American Society for Bone and Mineral Research |
| 2019 | Presidential Address, Musculoskeletal Tumor Society |
| 2018 | Legends of Iroquois Academic Hall of Fame, Iroquois School District Foundation |
| 2017 | Philip S. Hench Distinguished Alumnus Award, University of Pittsburgh School of Medicine |
| 2012 | Paula Stern Achievement Award, American Society for Bone and Mineral Research |
| 2010 | Komen Scholar, Susan G. Komen Foundation |
| 2009 | 15th Annual Donal Coffey Lecture, Society for Basic Urologic Research |
| 2009 | Jerry and Peg Throgmartin Professor of Oncology, Indiana University |
| 2009 | Legacy Laureate, University of Pittsburgh |
| 2008 | Elected Member, Association of American Physicians |
| 2004 | Elected Member, American Society for Clinical Investigation |
| 2002 | Gerald D. Aurbach Professor of Endocrinology, Endowed Chair, University of Virginia |
| 2002 | Mellon Investigator, University of Virginia Cancer Center |
| 2001 | Zachry Chair for Translational Research, Institute for Drug Development, CTRC |
| 2000 | Young Investigator Award, Advances in Mineral Metabolism |
| 1999 | Academic Award, Breast Cancer Program, US Army Department of Defense |
| 1999 | Fuller Albright Award, American Society for Bone and Mineral Research |
| 1998 | Best Doctors in America, National |
| 1998 | Outstanding Investigator Award, International Bone and Calcium Institute |
| 1998 | Research Day Award, Junior Faculty |
| 1996 - 1997 | Best Doctors in America, Central Region |
| 1996 | FIRST Award, NIH |
| 1992 | Clinical Investigator Award, NIH |
| 1992 | New Investigator Award, Breast Cancer Program, US Army Department of Defense |
| 1991 | Associate Investigator, Veterans Administration |
| 1991 | National Research Service Award, NIH |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2025. 380.Role of pathologic bone resorption on cognitive function: Implications for cancer and treatment. Invited. Cancer Neuroscience Scientific Retreat. Houston, Texas, US.
- 2016. Cancer-associated muscle weakness: what’s bone got to do with it?. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
Regional Presentations
- 2022. Systemic effects of pathologic bone remodeling. Houston, Texas, US.
- 2006. Skeletal complications of cancer and cancer treatment. Conference. Bone Club. San Antonio, TX, US.
- 1997. Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Conference. Texas Mineralized Tissue Society. Corpus Christi, TX, US.
- 1996. Treatment of osteoporosis: 1996 and Beyond. Conference. Texas Medical Association. San Antonio, TX, US.
National Presentations
- 2024. Anabolic agents and patients with cancer. Is there a role in bone health?. Invited, US.
- 2024. Bad to the Bone: Systemic Effects of Pathologic Bone Resorption. Invited. Pathology Grand Rounds. Denver, Colorado, US.
- 2024. Use of anabolic agents to treat osteoporosis. Invited, New Mexico, US.
- 2023. Why Do Hormone-Dependent Cancers Love Bone?. Invited. Enodcrine Society Annual Meeting ENDO 2023. Chicago, IL, US.
- 2023. Systemic effects of bone destruction on muscle function. Invited. Chicago, Illinois, US.
- 2023. Bad to the bone: effects of pathologic bone destruction on muscle. Special Symposium. Invited. American Association for Cancer Research Annual Meeting. Orlando, FL, US.
- 2023. Systemic effects of bone destruction on muscle function. Invited. Orlando, Florida, US.
- 2022. Breast cancer bone metastases and diabetes. Invited, California, US.
- 2022. Challenging bone cases. Invited. Austin, US.
- 2022. Bad to the bone: Systemic effects of pathological bone destruction. Major Symposium: Bone Metastases. Invited. American Association for Cancer Research Annual Meeting. New Orleans, LA, US.
- 2022. Bad to the bone: Systemic effects of pathological bone destruction. Invited. New Orleans, Louisiana, US.
- 2021. Systemic consequences of pathologic bone remodeling in cancer and cancer treatment. Haddad Memorial Lecture, US.
- Animal models of humoral hypercalcemia. Invited. University of Colorado Health Sciences Center. Denver, CO, US.
- Pathogenesis of humoral hypercalcemia. Invited. University of Colorado Health Sciences Center. Denver, CO, US.
International Presentations
- 2025. Brain-bone connection Korean Society of Bone and Mineral Research Meeting. Visiting, KR.
- 2025. Effects of pathologic bone resorption on cognition. Invited, KR.
- 2025. Systemic effects of pathologic bone destruction on muscle function,. Invited, KR.
- 2025. Cancer-associated cachexia. Invited, AT.
- 2025. The bone and brain connection. Excellence in Research Award. Invited, AT.
- 2025. Bad to the Bone: Systemic effects of pathologic bone destruction. Invited, BB.
- 2024. Use of denosumab in breast cancer: Against the motion. Panelist, CA.
- 2024. Challenging cases. Invited, GB.
- 2023. Use of anabolic agents for bone health in cancer patients. Invited. Vancouver, CA.
- 2021. Cancer, bone and beyond: an integrated view of the bone microenvironment and pathologic bone resorption. Invited. Crick International Cancer Conference, the Francis Crick Institute. London, GB.
- 365.Bad to the bone: systemic effects of pathologic bone destruction. Rudolph Möbauer Colloquium. Heidelberg, DE.
Formal Peers
- 2023. Cancer, bone and beyond: an integrated view of the bone microenvironment. Invited. Heidelberg, DE.
- 2021. Systemic consequences of pathologic bone remodeling in cancer and cancer treatment. Invited, US.
- 2021. Bad to the bone: Systemic effects of pathological bone destruction. Invited. Houston, TX, US.
- 2020. Cancer, bone and beyond: an integrated view of the bone microenvironment. Invited. New York, NY, US.
- 2019. Bone-derived TGF-β Impairs Glucose Metabolism and Insulin Release by Oxidation of RyR2 Ca2+ Release Channel in Pancreatic β-cells in the Setting of High Bone Turnover, Aging and High Fat Diet. Invited. Indianapolis, IN, US.
- 2019. Cancer-associated bone destruction: is there an effect on metabolism?. Invited. Durham, NC, US.
- 2019. Cancer-associated bone destruction: is there an effect on metabolism?. Invited. Tuscon, AZ, US.
- 2019. Role of bone-derived TGFß on glucose homeostasis: Implications for states increased bone destruction. Invited. Portland, OR, US.
- 2019. Cancer, bone, muscle and metabolism: what’s the connection?. Invited. Houston, TX, US.
- 2019. Cancer, bone, muscle and metabolism: what’s the connection?. Invited. Sacramento, CA, US.
- 2018. Beyond Jaws: an Exposé on Shark s. Invited. Erie, PA, US.
- 2018. Cancer, bone, muscle and metabolism: what’s the connection?. Invited. Dallas, TX, US.
- 2018. Cancer-associated muscle dysfunction: what’s bone got to do with it?. Invited. Philadelphia, PA, US.
- 2017. Cancer-associated muscle weakness: what’s bone got to do with it?. Invited. Ensenada, MX.
- 2017. Cancer-associated muscle weakness: role of the bone microenvironment. Invited. London, Ontario, CA.
- 2017. Cancer-associated muscle weakness: what’s bone got to do with it?. Invited. Leiden, NL.
- 2017. (1) Cancer-associated muscle weakness: what’s bone got to do with it? (2) Effect of bone destruction on metabolism. Invited. San Francisco, CA, US.
- 2017. (1) Cancer-associated muscle weakness: Role of bone-derived TGFβ (2) Cancer-associated muscle weakness: what’s bone got to do with it?. Invited. San Antonio, TX, US.
- 2016. Cancer-associated muscle weakness: what’s bone got to do with it?. Invited. Salt Lake City, UT, US.
- 2016. Bone-derived TGFß mediates muscle weakness associated with breast cancer bone metastases. Invited. Paris, FR.
- 2016. Bone-derived TGFß mediates muscle weakness associated with breast cancer bone metastases. Invited. Lyon, FR.
- 2016. Breast cancer-associated muscle weakness: what’s bone got to do with it?. Invited. Dallas, TX, US.
- 2016. Breast cancer-associated muscle weakness: what’s bone got to do with it?. Invited. Houston, TX, US.
- 2015. Bone-derived TGFß mediates muscle weakness associated with breast cancer bone metastases. Invited. Madrid, ES.
- 2015. Cancer-associated muscle weakness: what’s bone got to do with it?. Invited. Urbana, IL, US.
- 2015. Cancer, muscle and bone: it’s all about the microenvironment. Invited. St. John's, Newfoundland, CA.
- 2015. Cancer-associated muscle dysfunction: what’s bone got to do with it?. Invited. New York, NY, US.
- 2015. Prostate cancer bone metastases: role of the microenvironment. Invited. La Jolla, CA, US.
- 2014. Cancer-associated muscle dysfunction: role of the bone microenvironment. Invited. Los Angeles, CA, US.
- 2014. Cancer-associated muscle dysfunction: role of the bone microenvironment. Invited. Durham, NC, US.
- 2014. (1) Molecular mechanisms of bone metastases: implications for therapy (2) Molecular mechanisms of cancer-induced muscle dysfunction. Invited. South Bend, IN, US.
- 2014. Cancer-associated muscle dysfunction: Role of the bone microenvironment. Invited. Eddendorf, Hamburg, DE.
- 2014. Cancer-associated muscle weakness: the role of the bone microenvironment. Invited. Tampa, FL, US.
- 2013. Molecular mechanisms of breast cancer metastases to bone. Invited. Cleveland, OH, US.
- 2013. Cancer-associated muscle dysfunction: role of the bone microenvironment in ryanodine receptor remodeling. Invited. Tokyo, JP.
- 2012. Molecular mechanisms of bone metastases: implications for therapy. Invited. Lafayette, IN, US.
- 2012. TGFß in cancer and bone: Therapeutic opportunities and challenges. Invited. Denver, CO, US.
- 2011. Remodeling of ryanodine receptor in breast cancer-associated muscle weakness. Invited. New York, NY, US.
- 2011. Molecular mechanisms of bone metastases: implications for therapy. Invited. Ithaca, NY, US.
- 2011. Molecular mechanisms of bone metastases: implications for therapy. Invited. Madrid, ES.
- 2011. Molecular mechanisms of bone metastases: implications for therapy. Invited. New Brunswick, NJ, US.
- 2011. Molecular mechanisms of bone metastases: implications for therapy. Visiting. New York, NY, US.
- 2011. TGFß in cancer and bone. Visiting. Grand Rapids, MI, US.
- 2011. Biology of bone metastases due to breast and prostate cancer. Invited. Madrid, ES.
- 2010. Molecular mechanisms of TGF-ß signaling in bone metastases: implications for therapy. Invited. Tokushima, JP.
- 2010. What attracts tumor cells to bone?. Invited. Turku, FI.
- 2010. TGF-ß: Cancer, Bone and Beyond. Invited. Los Angeles, CA, US.
- 2010. What makes cancer cells home to bone?. Invited. Paris, FR.
- 2010. Differential signaling of TGF-ß in the bone microenvironment: Impact on tumor growth. Invited. Paris, FR.
- 2009. TGF-ß: Cancer, Bone and Beyond. Invited. Indianapolis, IN, US.
- 2009. (1) TGF-ß: Cancer, Bone and Beyond (2) Role of RANKL/RANK/OPG in skeletal complications of malignancy. Invited. Atlanta, GA, US.
- 2009. (1) TGF-ß: Cancer, Bone and Beyond (2) Role of RANKL/RANK/OPG in skeletal complications of malignancy. Invited. Pittsburgh, PA, US.
- 2009. TGF-ß: Cancer, Bone and Beyond. Invited. Leuven, BE.
- 2009. TGF-beta: Cancer, bone and beyond. Invited. Brisbane, AU.
- 2009. TGF-beta: Cancer, bone and beyond. Invited. Leiden, NL.
- 2008. TGF-beta: Cancer, bone and beyond. Visiting. Indianapolis, IN, US.
- 2008. Biology of bone metastases: Implications for therapy. Invited. Houston, TX, US.
- 2008. TFGβ: Cancer, bone and beyond. Invited. Montreal, Quebec, CA.
- 2008. Biology of bone metastases: Therapeutic implications. Invited. New Haven, CT, US.
- 2008. (1) Biology of bone metastases – Implications for therapy (2) TGFβ: Cancer, bone and beyond. Invited. Norfolk, VA, US.
- 2008. Biology of Bone Metastases: Implications for Therapy. Invited. Indianapolis, IN, US.
- 2008. Molecular mechanism of bone metastases: Insight into pathophysiology and treatment. Invited. Tokyo, JP.
- 2008. TGFβ: Cancer, bone and beyond. Invited. Sapporo, JP.
- 2008. TGFβ: Cancer, bone and beyond. Visiting. Boston, MA, US.
- 2008. TGFβ: Cancer, Bone and Beyond. Invited. Ann Arbor, MI, US.
- 2008. (1) TGFβ: Cancer, bone and beyond (2) The biology of bone metastases: Therapeutic implications. Invited. Pittsburgh, PA, US.
- 2008. Molecular mechanisms of bone metastases: Implications for therapy. Invited. Dallas, TX, US.
- 2008. TGFβ in cancer and bone: Friend or foe?. Invited. New Haven, CT, US.
- 2007. Role of TGF-beta in solid tumor metastases to bone: Implications for therapy. Invited. Nashville, TN, US.
- 2007. TGFβ signaling in cancer and bone: Friend or foe?. Invited. Birmingham, AL, US.
- 2007. TGFβ in cancer and bone: Friend or foe?. Invited. Miami, FL, US.
- 2007. Endothelins: Cancer, bone and beyond. Invited. Nashville, TN, US.
- 2007. TGFβ in cancer and bone: Friend or foe?. Invited. Rochester, NY, US.
- 2007. Endothelins in pathologic and normal bone remodeling. Invited. Pittsburgh, PA, US.
- 2007. Endothelins in pathologic and normal bone remodeling. Visiting. Collegeville, PA, US.
- 2007. TGFβ signaling in breast cancer bone metastases: Friend or foe?. Invited. Portland, OR, US.
- 2007. Skeletal health in the cancer patient. Invited. Portland, OR, US.
- 2007. TGFβ in bone metastases: Pathophysiology to treatment. Invited. New York, NY, US.
- 2007. TGFβ signaling in cancer metastases to bone: Friend or foe?. Invited. Cleveland, OH, US.
- 2006. Molecular mechanisms of bone metastases: Insight into therapy. Invited. San Antonio, TX, US.
- 2006. TGFβ in bone metastases: Pathophysiology to treatment. Visiting. Minneapolis, MN, US.
- 2006. Pathophysiology of metastases. Invited. San Francisco, CA, US.
- 2005. Molecular mechanisms of osteoblastic metastases: Implications for therapy. Invited. Niagara Falls, NY, US.
- 2005. Role of TGFß in breast cancer metastases to bone. Visiting. Boston, MA, US.
- 2005. Mechanisms of osteolytic metastases to bone: Implications for therapy. Visiting. Philadelphia, PA, US.
- 2005. Bone metastases: Molecular mechanisms and therapeutic interventions. Visiting. Baltimore, MD, US.
- 2004. TGFß blockade in bone metastases. Visiting. Cambridge, MA, US.
- 2004. Molecular mechanisms of bone metastases: Implications for therapy. Invited. New York, NY, US.
- 2004. Mechanisms of osteoblastic metastases. Invited. Worcester, MA, US.
- 2004. Endothelin axis in osteoblastic metastases: Implications for skeletal health. Invited. New Haven, CT, US.
- 2003. Molecular mechanisms of bone metastases. Invited. Birmingham, AL, US.
- 2003. Cancer migration of tumor cells to bone: The pathology of bone metastases. Invited. Augusta, GA, US.
- 2003. Role of bisphosphonates in metastatic breast cancer. Invited. Virginia Beach, VA, US.
- 2002. Disorders of calcium homeostasis. Invited. Victoria, TX, US.
- 2002. Molecular mechanisms of bone metastases: Implications for therapy. Invited. Salt Lake City, UT, US.
- 2002. Biology of metastasis in bone injury specific to breast cancer. Invited. Shreveport, LA, US.
- 2002. New advances in osteoporosis treatment: Role of PTH. Visiting. Greenville, NC, US.
- 2002. Molecular mechanisms of bone metastases: Implications for therapy. Invited. Long Island, NY, US.
- 2002. Hypercalcaemia of malignancy. Invited. Greenville, NC, US.
- 2002. Molecular mechanisms of bone metastases: Implications for therapy. Invited. San Francisco, CA, US.
- 2002. Molecular mechanisms of bone metastases: Implications for therapy. Invited. Palo Alto, CA, US.
- 2002. Molecular mechanisms of bone metastases: Implications for therapy. Visiting. South San Francisco, CA, US.
- 2001. Molecular mechanisms of bone metastases: Implications for therapy. Invited. New York, NY, US.
- 2001. Molecular mechanisms of osteolytic bone metastases due to breast cancer. Invited. Duarte, CA, US.
- 2001. Molecular mechanisms of bone metastases: Implications for therapy. Invited. Charlottesville, VA, US.
- 2001. Molecular mechanisms of osteolytic metastases: Implications for therapy. Invited. New York, NY, US.
- 2001. Molecular mechanisms of osteolytic metastases: implications for therapy. Invited. New York, NY, US.
- 2001. PTHrP in malignancy: Hypercalcemia and bone metastases. Invited. Atlanta, GA, US.
- 2001. Mechanisms of osteolytic bone metastases. Invited. Fayetteville, AR, US.
- 2001. Molecular mechanisms of bone metastases: osteolytic and osteoblastic. Invited. Richmond, VA, US.
- 2001. Hypercalcaemia of Malignancy. Visiting. Richmond, VA, US.
- 2000. Animal models of bone metastases. Invited. Bethesda, MD, US.
- 2000. Breast cancer metastases to bone: Role of PTHrP and TGFß. Invited. Pittsburgh, PA, US.
- 2000. PTHrP in malignancy: Hypercalcemia and bone metastases. Invited. Rootstown, OH, US.
- 2000. Molecular mechanisms of osteolytic metastases: Implications for therapy. Invited. Cleveland, OH, US.
- 2000. Osteoblastic bone metastases: Role of ET-1. Invited. Pittsburgh, PA, US.
- 2000. Molecular mechanisms of osteolytic metastases. Visiting. Philadelphia, PA, US.
- 2000. Molecular mechanisms of osteolytic bone metastases. Invited. Ann Arbor, MI, US.
- 2000. Role of PTHrP in malignancy. Invited. Detroit, MI, US.
- 2000. Molecular mechanisms of osteolytic metastases: implications for therapy. Invited. Baltimore, MD, US.
- 2000. Mechanisms of bone metastases. Invited. Houston, TX, US.
- 1999. Molecular mechanisms of bone metastases: osteolytic and osteoblastic. Invited. Farmington, CT, US.
- 1999. Molecular mechanisms of bone metastases. Invited. Montreal, Quebec, CA.
- 1999. Role of ET-1 in osteoblastic metastases: Mechanisms of bone gain and bone loss. Invited. Meriden, NH, US.
- 1999. Bone issues in the patient with breast cancer. Invited. San Francisco, CA, US.
- 1999. Pathogenesis of breast cancer metastases to bone: Role of PTHrP and TGFß. Invited. New Haven, CT, US.
- 1999. Pathophysiology of bone metastases. Visiting. Oklahoma City, OK, US.
- 1998. Mechanisms of bone metastases. Invited. Tokyo, JP.
- 1998. Bone metastases: Mechanisms responsible for osteolytic and osteoblastic lesions. Invited. Osaka, JP.
- 1998. Breast cancer metastases to bone: Role of PTHrP and TGFß. Invited. Houston, TX, US.
- 1998. Molecular Mechanisms of Bone Metastases. Invited. Hershey, PA, US.
- 1998. Mechanisms of bone metastases: osteolytic and osteoblastic. Invited. San Francisco, CA, US.
- 1998. New insights into the mechanism and treatment of bone metastases. Invited. San Francisco, CA, US.
- 1998. New insights into the mechanism and treatment of bone metastases. Invited. Fairfield, CA, US.
- 1998. Mechanisms of bone metastases: osteolytic and osteoblastic. Invited. San Francisco, CA, US.
- 1998. Breast cancer metastasis to bone: Role of PTHrP and TGFß. Invited. Winston-Salem, NC, US.
- 1998. Mechanisms of breast cancer metastasis to bone. Invited. Winston-Salem, NC, US.
- 1997. The role of PTHrP and TGFß in breast cancer metastasis to bone. Invited. Manchester, GB.
- 1997. The role of TGFß in breast cancer metastasis to bone. Invited. San Antonio, TX, US.
- 1996. Breast cancer-mediated osteolysis: Role of PTHrP and TGFß. Invited. Galveston, TX, US.
- 1995. Role of PTHrP in humoral hypercalcemia and breast cancer metastasis to bone. Invited. Kenilworth, NJ, US.
- 1995. Role of PTHrP in the pathogenesis of breast cancer-mediated bone metastases. Invited. San Antonio, TX, US.
- 1995. PTHrP in the pathogenesis of breast cancer-mediated osteolysis. Invited. San Francisco, US.
- 1994. The role of PTHrP in malignancy. Invited. Ann Arbor, MI, US.
- 1993. Animal models of hypercalcemia. Invited. San Antonio, TX, US.
Grant & Contract Support
| Date: | 2021 - 2024 |
| Title: | Faculty STARs Award |
| Funding Source: | University of Texas |
| Role: | PI |
| Date: | 2020 - 2025 |
| Title: | Cancer Research Prevention Institute of Texas (CPRIT) RR190108 Established Investigator Award |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RR190108 |
| Date: | 2019 - 2024 |
| Title: | Molecular Mechanisms of Chemotherapy-Induced Cognitive Dysfunction |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| ID: | R50CA243887 |
| Date: | 2018 - 2024 |
| Title: | Role of bone marrow fat on breast cancer growth in bone |
| Funding Source: | Dive into the Pink |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Patil, MD, Wangsiricharoen, S, Lazar, A, Moon, BS, Madewell, JE, Collins, MT, Guise, TA. Approach to determining etiology of hypophosphatemia in a patient with coexisting phosphaturic mesenchymal tumor and fibrous dysplasia. JBMR Plus 9(1), 2025. e-Pub 2025. PMID: 39664934.
- Seibert, T, Shi, L, Althouse, S, Hoffman, R, Schneider, BP, Russ, KA, Altherr, CA, Warden, SJ, Guise, TA, Coggan, AR, Ballinger, TJ. Molecular and clinical effects of aromatase inhibitor therapy on skeletal muscle function in early-stage breast cancer. Scientific reports 14(1), 2024. e-Pub 2024. PMID: 38200207.
- Plett, PA, Chua, HL, Wu, T, Sampson, CH, Guise, TA, Wright, LE, Pagnotti, GM, Feng, H, Chin-Sinex, HJ, Pike, F, Cox, GN, MacVittie, TJ, Sandusky, GE, Orschell, CM. Effect of Age at Time of Irradiation, Sex, Genetic Diversity, and Granulopoietic Cytokine Radiomitigation on Lifespan and Lymphoma Development in Murine H-ARS Survivors. Radiation research 202(3):580-598, 2024. e-Pub 2024. PMID: 39099001.
- Boire, A, Burke, K, Cox, TR, Guise, TA, Jamal-Hanjani, M, Janowitz, T, Kaplan, RN, Lee, R, Swanton, C, Heiden, MG, Sahai, E. Why do patients with cancer die?. Nature Reviews Cancer 24(8):578-589, 2024. e-Pub 2024. PMID: 38898221.
- Yang, HS, Pan, W, Wang, Y, Zaydman, MA, Spies, NC, Zhao, Z, Guise, TA, Meng, QH, Wang, F. Generalizability of a Machine Learning Model for Improving Utilization of Parathyroid Hormone-Related Peptide Testing across Multiple Clinical Centers. Clinical chemistry 69(11):1260-1269, 2023. e-Pub 2023. PMID: 37738611.
- Liu, Y, Reiken, S, Dridi, H, Yuan, Q, Mohammad, KS, Trivedi, T, Miotto, MC, Wedderburn-Pugh, K, Sittenfeld, L, Kerley, Y, Meyer, JA, Peters, JS, Persohn, SA, Bedwell, AA, Figueiredo, LL, Suresh, S, She, Y, Soni, RK, Territo, PR, Marks, AR, Guise, TA. Targeting ryanodine receptor type 2 to mitigate chemotherapy-induced neurocognitive impairments in mice. Science translational medicine 15(715), 2023. e-Pub 2023. PMID: 37756377.
- Trivedi T, Manaa M, John S, Reiken S, Murthy S, Pagnotti GM, Dole NS, She Y, Suresh S, Hain BA, Regan J, Ofer R, Wright L, Robling A, Cao X, Alliston T, Marks AR, Waning DL, Mohammad KS, Guise TA. Zoledronic acid improves bone quality and muscle function in a high bone turnover state. bioRxiv, 2023. e-Pub 2023. PMID: 37333318.
- Pagnotti GM, Trivedi T, Wright LE, John SK, Murthy S, Pattyn RR, Willis MS, She Y, Suresh S, Thompson WR, Rubin CT, Mohammad KS, Guise TA. Low-Magnitude Mechanical Signals Combined with Zoledronic Acid Reduce Musculoskeletal Weakness and Adiposity in Estrogen-Deprived Mice. bioRxiv, 2023. e-Pub 2023. PMID: 36993656.
- Lui MS, Clemente-Gutierrez U, Vodopivec DM, Chang SL, Shirali AS, Huang BL, Chiang YJ, Fisher SB, Grubbs EG, Guise, TA, Graham PH, Perrier ND. Parathyroidectomy for Normocalcemic Primary Hyperparathyroidism is Associated with Improved Bone Mineral Density Regardless of Postoperative Parathyroid Hormone Levels. World J Surg 47(2):363-370, 2023. e-Pub 2023. PMID: 36195677.
- Calvert RD, Fleet JC, Fournier PGJ, Juarez P, Burcham GN, Haverkamp JM, Guise, TA, Ratliff TL, Elzey BD. Monocytic Myeloid-Derived Suppressor Cells from Tumor Tissue Are a Differentiated Cell with Limited Fate Plasticity. Immunohorizons 6(12):790-806, 2022. e-Pub 2022. PMID: 36480485.
- Roberts G, Benusiglio PR, Bisseling T, Coit D, Davis JL, Grimes S, Guise, TA, Hardwick R, Harris K, Mansfield PF, Rossaak J, Schreiber KC, Stanich PP, Strong VE, Kaurah P, Group LS. International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the Life after Prophylactic Total Gastrectomy (LAP-TG) study. Gastric Cancer 25(6):1094-1104, 2022. e-Pub 2022. PMID: 35831514.
- Arellano DL, Juárez P, Verdugo-Meza A, Almeida-Luna PS, Corral-Avila JA, Drescher F, Olvera F, Jiménez S, Elzey BD, Guise, TA, Fournier PGJ. Bone Microenvironment-Suppressed T Cells Increase Osteoclast Formation and Osteolytic Bone Metastases in Mice. J Bone Miner Res 37(8):1446-1463, 2022. e-Pub 2022. PMID: 35635377.
- Liu H, He J, Bagheri-Yarmand R, Li Z, Liu R, Wang Z, Bach DH, Huang YH, Lin P, Guise, TA, Gagel RF, Yang J. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma. Nat Commun 13(1):3684, 2022. e-Pub 2022. PMID: 35760800.
- Guise, TA, Wysolmerski JJ. Cancer-Associated Hypercalcemia. Reply. N Engl J Med 386(26):2540, 2022. e-Pub 2022. PMID: 35767456.
- Trivedi T, Guise, TA. Systemic effects of abnormal bone resorption on muscle, metabolism, and cognition. Bone 154:116245, 2022. e-Pub 2021. PMID: 34718221.
- Trivedi T, Pagnotti GM, Guise, TA, Mohammad KS. The Role of TGF-β in Bone Metastases. Biomolecules 11(11), 2021. e-Pub 2021. PMID: 34827641.
- Brown JE, Wood SL, Confavreux C, Abe M, Weilbaecher K, Hadji P, Johnson RW, Rhoades JA, Edwards CM, Croucher PI, Juarez P, El Badri S, Ariaspinilla G, D'Oronzo S, Guise TA, Van Poznak C. Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations. J Bone Oncol 29:100375, 2021. e-Pub 2021. PMID: 34131559.
- Nagata Y, Miyagawa K, Ohata Y, Petrusca DN, Pagnotti GM, Mohammad KS, Guise TA, Windle JJ, David Roodman G, Kurihara N. Increased S1P expression in osteoclasts enhances bone formation in an animal model of Paget's disease. J Cell Biochem 122(3-4):335-348, 2021. e-Pub 2021. PMID: 33107091.
- Patterson AM, Wu T, Chua HL, Sampson CH, Fisher A, Singh P, Guise TA, Feng H, Muldoon J, Wright L, Plett PA, Pelus LM, Orschell CM. Optimizing and Profiling Prostaglandin E2 as a Medical Countermeasure for the Hematopoietic Acute Radiation Syndrome. Radiat Res 195(2):115-127, 2021. e-Pub 2021. PMID: 33302300.
Review Articles
- Hadji, P, Aapro, M, Al-Dagri, N, Alokail, M, Biver, E, Body, JJ, Brandi, ML, Brown, JE, Confavreux, C, Cortet, B, Drake, M, Ebeling, PR, Eriksen, EF, Fuleihan, GH, Guise, TA, Harvey, NC, Kurth, A, Langdahl, BL, Lems, W, Matijevic, R, McCloskey, EV, Nappi, R, Palacios, S, Pfeiler, G, Reginster, JY, Rizzoli, R, Santini, D, Tuzun, S, Poznak, CV, Villiers, TD, Zillikens, Mc, Coleman, R. Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer. Journal of Bone Oncology 53, 2025. e-Pub 2025. PMID: 40726588.
- Nebgen DR, Domchek SM, Kotsopoulos J, de Hullu JA, Crosbie EJ, Paramanandam VS, Brood-van Zanten MMA, Norquist BM, Guise T, Rozenberg S, Kurian AW, Pederson HJ, Yuksel N, Michaelson-Cohen R, Bober SL, da Silva Filho AL, Johansen N, Guidozzi F, Evans DG, Menon U, Kingsberg SA, Powell CB, Grandi G, Marchetti C, Jacobson M, Brennan DJ, Hickey M. Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations. BJOG 130(12):1437-1450, 2023. e-Pub 2023. PMID: 37132126.
- Ballinger TJ, Thompson WR, Guise, TA. The bone-muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health. Breast Cancer Res 24(1):84, 2022. e-Pub 2022. PMID: 36419084.
- Guise, TA, Wysolmerski JJ. Cancer-Associated Hypercalcemia. N Engl J Med 386(15):1443-1451, 2022. e-Pub 2022. PMID: 35417639.
- Handley NR, Feng FY, Guise TA, D'Andrea D, Kelly WK, Gomella LG. Preserving Well-being in Patients With Advanced and Late Prostate Cancer. Urology 155:199-209, 2021. e-Pub 2020. PMID: 33373704.
- Pagnotti GM, Thompson WR, Guise, TA, Rubin CT. Suppression of Cancer-associated bone loss through dynamic mechanical loading. Bone 150:115998, 2021. e-Pub 2021. PMID: 33971314.
- Hussain A, Tripathi A, Pieczonka C, Cope D, McNatty A, Logothetis C, Guise T. Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 24(2):290-300, 2021. e-Pub 2021. PMID: 33028943.
Book Chapters
- Loots, GG, Guise, TA. Mechanisms Underlying Osteolytic and Osteoblastic Bone Metastases, 17-35, 2024.
- Joseph D, Guise TA. Approach to the patient with hypercalcemia. In: Oxford Textbook of Clinical Nephrology. Fourth. Oxford Prss, 2015.
- Clines GA, Guise TA. Hypercalcemia of malignancy. In: Medical Care of Cancer Patients. Peoples Medical Publishing House, 188-193, 2009.
- Heras-Herzig A, Kozlow W, Brown S, Guise TA. Osteoporosis associated with cancer and cancer treatment. In: Osteoporosis. Third. Academic Press, 1337-1374, 2008.
- Bartholin, L, Guise, TA. TGF in breast cancer osteolysis. In: TGF in Health and Disease, 2007.
- Clines GA, Guise TA. Mechanisms of bone destruction and bone formation by metastatic tumors. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Sixth. American Society for Bone and Mineral Research, 2006.
- Heras-Herzig A, Guise TA. Disorders of calcium metabolism. In: Therapy of Renal Diseases and Related Disorders. Fourth. Kluwer Academic Publishers, 2006.
- Clines GA, Chirgwin JM, Guise TA. Skeletal complications of malignancy: Central role for the osteoclast. In: Topics in Bone Biology. Springer-Verlag, 151-174, 2005.
- Mohammad KS, Guise TA. Osteoblastic bone metastases. In: Bone Metastases. First. Chung, 2004.
- Guise TA, Chirgwin JM. Biology of bone metastases. In: Diseases of the Breast. Third. Lippman, Morrow and Osborne, 1285-1296, 2004.
- Clines GA, Guise TA. Hypercalcaemia in hematologic malignancies and in solid tumors associated with extensive localized bone destruction. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Fifth. American Society for Bone and Mineral Research, 251-253, 2003.
- Guise, TA. Therapy affecting bone resorption and deposition. In: Management of Metastatic Disease to the Musculoskeletal System. Quality Medical Publishing, 107-138, 2002.
- Mundy GR, Yoneda T, Guise TA, Oyajobi B. Local factors in skeletal malignancy. In: Principles of Bone Biology. Second. Academic Press, 1093-1104, 2002.
- Bruder JA, Guise TA, Mundy GR. Disorders of calcium metabolism. In: Endocrinology and Metabolism. Fourth. McGraw Hill Book Company, 1079-1159, 2001.
- Mundy GR, Guise TA. Pathophysiology of bone metastasis. In: Cancer and the Skeleton. Martin Dunitz Ltd, 43-64, 2000.
- Guise TA, Mundy GR. Disorders of calcium homeostasis. In: The Kidney: Physiology and Pathophysiology. Third. Lippincott, Williams & wilkins, 1811-1839, 2000.
- Mundy GR, Guise TA. Biology of bone metastases. In: Diseases of the Breast. Second. Lippman, Morrow and Osborne, 911-920, 1999.
- Mundy GR, Yoneda T, Guise TA. Hypercalcaemia in hematologic malignancies and in solid tumors associated with extensive localized bone destruction. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Fourth. Lippincott Williams & Wilkins, 208-212, 1999.
- Guise TA, Mundy GR. Disorders of calcium metabolism. In: Therapy of Renal Diseases and Related Disorders. 3rd. Kluwer Academic Publishers, 85-114, 1997.
Letters to the Editor
- Kiel, DP, Guise, TA, Styner, M, Rubin, J. Concerns about the paper, “Benefits of targeted vibration for bone strength and bone density in postmenopausal women with osteopenia. JBMR Plus 9, 2025.
Patents
- Yoneda T, Mundy GR, Guise TA. Method to ameliorate osteolysis and metastasis. Patent Number: 5,993,817.
Patient Reviews
CV information above last modified February 09, 2026